TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK3328 (MK-3328-001)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Part I:~* Participant is male or female of non-reproductive potential between 50 and 65 years old.~* Participant is less than 6'5 tall~* Participant is in good health~* Participant has been a non-smoker for at least 10 years~Parts II and III:~* Male or female of non-reproductive potential at least 55 years of age~* Participant is cognitively normal (HE participants), or has probable mild-to moderate AD (AD participants)~* Participant is willing to have an arterial catheter placed in the radial artery (Part II only)~Exclusion Criteria:~Part I:~* Participant has a history of stroke, seizures, or neurological disorder~* Participant has or has a history of any disease or condition, or takes any medication that would interfere with assessment of the tracer or make participation unsafe or unduly uncomfortable~Parts II and III:~* Participant has a history or current evidence of any neurological or neurodegenerative disorder other than AD that is associated with altered cognition~* Participant has or has a history of any disease or condition, or takes any medication that would interfere with assessment of the tracer or make participation unsafe or unduly uncomfortable~* Participant is living in a nursing home or skilled nursing facility

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Part I, Healthy Participants (Type: EXPERIMENTAL): Healthy participants will receive a single intravenous (IV) dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part I of the study
- Part II, HE and AD Participants (Type: EXPERIMENTAL): HE and AD participants will receive a single IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part II of the study
- Part III, HE and AD Participants (Type: EXPERIMENTAL): HE and AD participants will receive two separate IV doses of \~150 megabecquerel (MBq) \[18F\]MK-3328 in Part III of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Xuebijing Injection on Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be eligible for inclusion if all of the inclusion criteria are met~1. Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM)~2. 18≤ age ≤75years~3. 2 ≤SOFA ≤13~4. obtain informed consent~Exclusion Criteria:~1. Diagnosis of sepsis for more than 48 h;~2. Pregnant and lactating women;~3. Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);~4. Severe liver and kidney dysfunction (single liver or kidney SOFA score ≥ 3 points);~5. Use of an immunosuppressant or having an organ transplant within the previous 6 months;~6. Participating in other clinical trials in the previous 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): 100ml Xuebijing Injection will be dissolved in 100 mL of normal saline every 12 hours for 5 days in blind fashion.
- Placebo group (Type: PLACEBO_COMPARATOR): normal saline 200 mL every 12 hours for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Trazodone on Sleep Apnea Severity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for OSA Patients:~* OSA (elevated AHI).~* Age range 18-70 years.~Exclusion Criteria:~* Any known cardiac (apart from treated hypertension), pulmonary (including asthma), renal, neurologic (including epilepsy), neuromuscular, or hepatic disease.~* Susceptible to stomach ulcers.~* Pregnant women.~* History of hypersensitivity to Afrin, Lidocaine, trazodone and/or donepezil.~* History of bleeding diathesis and/or gastrointestinal bleeding.~* Use of any medications that may affect sleep or breathing.~* A psychiatric disorder, other than mild depression; e.g. schizophrenia, bipolar disorder, major depression, panic or anxiety disorders.~* Substantial cigarette (\>5/day), alcohol (\>3oz/day) or use of illicit drugs.~* More than 10 cups of beverages with caffeine (coffee, tea, soda/pop) per day.~* Desaturations to below 70% lasting greater than 10 seconds in duration per event on polysomnography.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive a sugar pill during their placebo night sleep study.
- Trazodone (Type: ACTIVE_COMPARATOR): Subjects will receive trazodone during their treatment night sleep study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 365-569 days of age.~Exclusion Criteria:~* Subjects who already received a booster dose of Hib vaccine.~* History of serious reaction(s) following vaccination.~* Any vaccination within 7 days of study vaccination.~* Known or suspected immune impairment.

- Gender: ALL
- Minimum Age: 365 Days
- Maximum Age: 569 Days
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of migraine as defined by International Headache Society (IHS) International Classification of Headache Disorders (ICHD)-3 beta version (1.1 or 1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to screening, migraine onset prior to age 50 and MONTHLY frequency of 4-14 MHD.~Exclusion Criteria:~* Are currently enrolled in or have participated within the last 30 days or within 5 half-lives (whichever is longer) in a clinical trial involving an investigational product.~* Current use or prior exposure to galcanezumab or another Calcitonin Gene-Related Peptide (CGRP) antibody.~* Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins, or to galcanezumab.~* History of persistent daily headache, cluster headache or migraine subtypes including hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Galcanezumab 120mg (Type: EXPERIMENTAL): Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
- Galcanezumab 240mg (Type: EXPERIMENTAL): Galcanezumab 240mg given by SC injection once a month for 6 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given by SC injection once a month for 6 months.
- Galcanezumab 120mg Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): Galcanezumab 240mg given as loading dose at first dosing visit followed by galcanezumab 120mg once a month for 5 months by subcutaneous (SC) injection.
- Galcanezumab 240mg Maximum Extended Enrollment Cohort (Type: EXPERIMENTAL): Galcanezumab 240mg given by SC injection once a month for 6 months.
- Placebo Maximum Extended Enrollment Cohort (Type: PLACEBO_COMPARATOR): Placebo given by SC injection once a month for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Antiplatelet Effects Comparing Ticagrelor (Ticag. - AZD6140) With Clopidogrel (Clop.) Responder and Non-responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented stable Coronary Artery Disease (CAD) (stable angina, previous MI history, previous history of revascularization)~* Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal contraceptive in addition to double barrier contraception~Exclusion Criteria:~* History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or coronary artery bypass graft (CABG))~* Any acute or chronic unstable condition in the past 30 days~* Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low platelet count, recent major trauma~* History of intolerance or allergy to aspirin or clopidogrel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aspirin + Ticagrelor
- 2 (Type: ACTIVE_COMPARATOR): Aspirin + Clopidogrel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Written informed consent~* History of bronchial asthma~* FEV1 more than or equal to 60% of predicted~* Stable asthma~* Patients who are in good health with the exception of asthma~Main Exclusion Criteria:~* Concomitant severe diseases, diseases expected to interfere with the outcome of the study, or diseases which are contraindications for the use of ICS~* COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function~* Use of ICS 4 weeks before entry into the baseline period~* Pregnancy~* Intention to become pregnant during the course of the study~* Breast feeding~* Lack of safe contraception~* Use of other drugs not allowed~* Current smokers and ex-smokers with more than or equal to 10 pack-years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe hypertension (MSDBP ≥ 100 mmHg and \< 120 mmHg, MSSBP ≥ 145 mmHg and \< 200 mmHg).~Exclusion Criteria:~* Patients on two or more antihypertensive drugs with MSSBP ≥ 180 mmHg and/or MSDBP ≥ 110 mmHg at Visit 1.~* Patients on three or more antihypertensive drugs with MSDBP ≥ 90 mmHg and \< 110 mmHg, and/or MSSBP ≥ 140 mmHg and \< 180 mmHg at Visit 1.~* Patients on four or more antihypertensive drugs at Visit 1.~* Arm circumference \> 42 cm for patients participating in ABPM.~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Golimumab in Participants With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with diagnosis of definite ankylosing spondylitis for at least 3 months based on modified New York radiographic and clinical criteria~* Participants with symptoms of active disease at screening and at baseline~* Participant has either an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAID) over a 4 week period in total with maximal recommended doses of NSAIDs, or is unable to receive a full 4 weeks of maximal NSAID therapy because of intolerance, toxicity, or contraindications to NSAIDs~* Participants with C- reactive protein (CRP) level of greater than or equal to (\>=) 0.3 milligram per deciliter (mg/dL) at screening~* Additional protocol-defined inclusion criteria apply~Exclusion Criteria:~* Participant with other inflammatory diseases that might confound the evaluations of benefit from the golimumab therapy~* Pregnant or lactating females~* Participants with chest radiograph within 3 months prior to the first administration of study agent that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis~* Participants who had a serious infection (including but not limited to, hepatitis, pneumonia, sepsis, or pyelonephritis), or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study agent~* Additional protocol-defined exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group 1: Placebo then Golimumab (Type: EXPERIMENTAL): Participants will receive intravenous infusions of placebo at Weeks 0, 4 and 12. At Week 16, all participants receiving placebo will begin receiving intravenous infusions of golimumab 2 milligram per kilogram (mg/kg) at Weeks 16, 20 and thereafter every 8 weeks up to Week 52.
- Treatment Group 2: Golimumab (Type: EXPERIMENTAL): Participants will receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 16, participants will receive a placebo infusion to maintain the blind.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alzheimer's in Long-Term Care--Treatment for Agitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No age limit~* probable/possible Alzheimer's disease diagnosis~* disruptive agitated behaviors (e.g., irritability, aggression, uncooperativeness, pacing)~* no hypotension~* no concurrent use of alpha-1-blockers~* no delirium, schizophrenia, mania, psychotic symptoms.~Exclusion Criteria:~* Cardiovascular: unstable angina, recent myocardial infarction, second or third degree atrioventricular (AV) block, preexisting hypotension (systolic blood pressure less than 110) or orthostatic hypotension~* Other medical exclusions: chronic renal or hepatic failure, or any unstable medical condition~* Exclusionary medications: current treatment with prazosin, other alpha-1-blockers~* Current enrollment in a separate investigational drug trial~* Psychoactive medications: subjects may be psychoactive medication-free or be partial responders (by subjective assessment of referring health care professional) to one psychoactive medication from any of the following classes: antipsychotics, anticonvulsants, mood stabilizers, antidepressants, benzodiazepines, or buspirone. Partial response is defined as some improvement in agitated behavior but persistence of agitated behaviors severe enough to cause patient distress and/or difficulty with caregiving. Although not formally rated, this improvement is equivalent to a Clinical Global Impression of Change (CGIC) rating of no more than minimal improvement (improvement is noticed by not enough to improve patient function or caregiver's practical management of the patient).~* Psychiatric/behavioral: lifetime schizophrenia; current delirium, mania, depression, or uncontrolled persistent distressing psychotic symptoms (hallucinations, delusions), substance abuse, panic disorder, or any behavior which poses an immediate danger to patient or others or which results in the patient being too uncooperative to meet the requirements of study participation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- prazosin (Type: ACTIVE_COMPARATOR): None
- placebo (inert substance) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. Chronic hepatitis C genotype 1 infection, diagnosed at least 6 months prior to screening~2. Treatment naive or confirmed prior treatment relapse or partial response following treatment with interferon and ribavirin~3. Age 18 to 70 years~4. HCV RNA (Hepatitis C Virus RiboNucleic Acid) = 1,000 IU/mL at screening~5. Liver biopsy or fibroscan to exclude cirrhosis~Exclusion criteria:~1. Hepatitis C Virus (HCV) infection of mixed genotype; Hepatitis B Virus (HBV) or Human Immunodeficiency Virus (HIV) co-infection~2. Evidence of acute or chronic liver disease due to causes other than chronic HCV infection,~3. Decompensated liver disease, or history of decompensated liver disease,~4. Body weight \< 40 or \> 125 kg,~5. Clinical evidence of significant or unstable cardiovascular disease, chronic pulmonary disease, history or evidence of retinopathy or clinically significant ophthalmological disorder~6. Pre-existing psychiatric condition that could interfere with the subject's participation in and completion of the study~7. Laboratory parameters disorders (thalassemia major, sickle cell anemia or glucose 6 phosphate dehydrogenase deficit)~8. Hemoglobin \< 12 g/dL for women and \< 13 g/dL for men~9. Patients who have been previously treated with at least one dose of any antiviral or immunomodulatory drug other than interferon alfa or ribavirin for acute or chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Effect of BI 207127 on BI 201335, the effect of BI 201335 and dual oral direct acting antiviral (DAAs) on caffeine, tolbutamide and midazolam
- Group B (Type: EXPERIMENTAL): Effect of BI 201335 on BI 207127, the effect of BI 207127 and metabolites and dual oral DAAs on caffeine, tolbutamide and midazolam
- Group C (Type: EXPERIMENTAL): Effect of Dual oral DAAs on tenofovir
- Group D (Type: EXPERIMENTAL): Effect of BI 201335 and BI 207127 at 600 mg b.i.d. on caffeine, tolbutamide and midazolam
- Group E (Type: EXPERIMENTAL): Effect of BI 201335 and BI 207127 on raltegravir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Effect of Stochastic Resonance Vibration on Gait and Balance and Upper Extremity Function in Children With Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with cerebral palsy~* 3 years to 18 years of age~* Able to reliably express pain, discomfort or fear as reported by the parent/guardian~* Manual ability classification scale (MACS) levels I, II or III~Exclusion Criteria:~* Any unstable medical condition. An unstable medical condition is a state of imminent threat to life such as shock, acute asthma, respiratory distress, severe infection and sepsis. Any patient in a clinic or therapy center presenting with signs and symptoms of an unstable medical condition will be directed to emergency medical services~* Any medical condition preventing active rehabilitation reported by the parent/guardian such as:~  o Thromboembolic disease, acute progressive neurological disorder, cardiovascular or pulmonary contraindications, aggressive behavior, severe cognitive deficits, joint instabilities and compromised bone health, recent or non-consolidated fractures, osteoporosis~* Subjects with cardiac pacemakers, electronic pumps or any other implanted medical devices~* Skin lesions affecting the areas where the device straps will be attached to the body

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- stochastic resonance (SR) vibration (Type: EXPERIMENTAL): SR applied sub threshold at 90% of participant's detection threshold
- Sham treatment (Type: SHAM_COMPARATOR): SR devices worn but not turned on (0% of participant's detection threshold).
- Unblinded treatment (Type: EXPERIMENTAL): SR is applied above participant's detection threshold at a participant selected intensity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete